-
Published13/10/2025
-
Today07/11/2025
-
Deadline05/10/2027
Utilities
- indicates text translated automatically in your browsing language
Open framework agreement on pharmaceutical discounts pursuant to § 130a(8) SGB V with the possibility of accession at any time, so-called marketing authorisation model 2025-10 Text automatically translated in your browsing language Automatically translated
This notice is intended to conclude agreements with pharmaceutical companies within the meaning of Section 130a(8) sentence 1 SGB V. The invitation to participate is addressed only to pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4(18) of the German Medicines Act. It is not an open procedure pursuant to § 15 VgV in conjunction with § 119(3) GWB, but a publication of the invitation to conclude/join/discount contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the discount. Contractual partners may become an unlimited number of pharmaceutical entrepreneurs or employee groups of pharmaceutical entrepreneurs within the meaning of Section 4(18) of the Pharmaceuticals Act. Text automatically translated in your browsing language Automatically translated
https://www.kbs.de/DE/UeberUns/Ausschreibungen/EU/EU_node.html
https://www.kbs.de/DE/UeberUns/Ausschreibungen/EU/EU_node.html
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.